Palisade Bio (PALI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on October 17, 2025, with voting available online, by phone, or by mail.
Three main proposals are up for vote: election of three directors, ratification of the independent auditor, and approval of a reverse stock split.
Only stockholders of record as of September 12, 2025, are eligible to vote.
Voting matters and shareholder proposals
Proposal 1: Elect three directors (J.D. Finley, Donald Williams, Emil Chuang) for a one-year term expiring at the 2026 annual meeting.
Proposal 2: Ratify Baker Tilly US, LLP as the independent registered public accounting firm for 2025.
Proposal 3: Approve a reverse stock split at a ratio between 1-for-5 and 1-for-50, at the Board's discretion, to be effected by December 31, 2025.
No other matters are expected to be presented for a vote.
Board of directors and corporate governance
The Board consists of four members, three of whom are independent as per Nasdaq rules.
The classified board structure was removed in February 2024; all directors are now elected annually.
The Board has Audit, Compensation, and Governance and Nominating Committees, all with independent members.
The Board Chair is independent, and the Board meets regularly, with all directors attending at least 75% of meetings in 2024.
A Code of Business Conduct and Ethics and an insider trading policy are in place.
Latest events from Palisade Bio
- PALI-2108 shows strong safety, efficacy, and precision targeting for IBD, advancing to Phase 2.PALI
Corporate presentation23 Mar 2026 - Strong cash position and positive clinical progress support advancement of IBD pipeline.PALI
Q4 202520 Mar 2026 - PALI-2108 shows promise as a safe, effective, once-daily oral IBD therapy with dual action.PALI
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Advancing a once-daily, gut-restricted PDE4 inhibitor with strong funding and pivotal trials ahead.PALI
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Advancing a locally-activated PDE4 inhibitor for UC, with phase I trials and pharma interest ahead.PALI
Virtual Investor Closing Bell Series3 Feb 2026 - Lead drug for ulcerative colitis targets higher remission rates with fewer side effects, entering trials soon.PALI
Virtual Investor Pitch Conference3 Feb 2026 - PALI-2108 demonstrates targeted efficacy and safety in IBD, with major market potential.PALI
Virtual Investor "Top 5 for '25"14 Jan 2026 - 8.9M shares registered for resale; lead IBD drug faces clinical and Nasdaq risks.PALI
Registration Filing16 Dec 2025 - Definitive Phase II trials in UC and Crohn's, backed by $138M, target rapid, safe efficacy.PALI
Piper Sandler 37th Annual Healthcare Conference6 Dec 2025